Table 1. Patient characteristics.
| Total N = 20 | Ridaforolimus 22 mg/m2 n = 4 | Ridaforolimus 28 mg/m2 n = 3 | Ridaforolimus 33 mg/m2 n = 13 | |
|---|---|---|---|---|
| Median age, years (range) | 13.0 (8–17) | 13.5 (8–17) | 15.0 (12–17) | 12.0 (8–17) |
| Gender, n (%) | ||||
| Male | 8 (40) | 1 (25) | 2 (67) | 5 (38) |
| Female | 12 (60) | 3 (75) | 1 (33) | 8 (62) |
| Tumor diagnosis, n (%) | ||||
| Ependymoma (1 anaplastic and 3 NOS) | 4 (20) | 1 (25) | 1 (33) | 2 (15) |
| Ewing sarcoma/peripheral primitive neuroectodermal tumor | 3 (15) | 1 (25) | 0 | 2 (15) |
| Osteosarcoma | 3 (15) | 1 (25) | 1 (33) | 1 (8) |
| Neuroblastoma | 2 (10) | 0 | 0 | 2 (15) |
| Othera | 8 (40) | 1 (25) | 1 (33) | 6 (46) |
| Number of prior therapies, n (%) | ||||
| 1 | 8 (40) | 2 (50) | 1 (33) | 5 (38) |
| 2 | 3 (15) | 0 | 0 | 3 (23) |
| 3 | 3 (15) | 1 (25) | 0 | 2 (15) |
| ≥4 | 4 (20) | 1 (25) | 2 (67) | 1 (8) |
| Unknown | 2 (10) | 0 | 0 | 2 (15) |
a
Other includes 1 patient each with: adrenocortical carcinoma; classical Hodgkin lymphoma; diffuse intrinsic pontine glioma; glioblastoma multiforme; pineoblastoma; soft tissue neoplasm, NOS; synovial sarcoma; and Wilms tumor (nephroblastoma).
NOS, not otherwise specified.